Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma

Sponsor
Peking University
Study ID
NCT04239170
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an open-label, single arm, Phase 2 study to evaluate efficacy and safety of PD1 inhibitor Camrelizumab(SHR-1210) combined with Gemox in patients with relapsed and refractory hodgkin lymphoma who will receive ASCT.Efficacy will be assessed according to 2014 Lugano criteria.

Key Dates

Start date
Jan 31, 2020
Status verified
Jan 2020
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022

Study Design

Enrollment
84 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab(SHR-1210) Combined With GEMOX

Primary Outcome Measure

Complete Response [ Time Frame: From first patient first visit to 3 month after last patient first visit ]

Central Contacts

Related Studies